MicroRNA-138通过靶向SGTA调控非霍奇金淋巴瘤细胞黏附介导的耐药表型
研究探讨miR-138靶向SGTA对非霍奇金淋巴瘤细胞黏附介导的耐药表型的影响。以纤连蛋白或HS-5细胞构建黏附模型,发现黏附培养上调miR-138表达,过表达miR-138抑制SGTA 3'UTR荧光素酶活性并诱导G(1)期停滞。35例弥漫大B细胞淋巴瘤样本中,进展/稳定患者miR-138表达显著高于完全/部分缓解患者。结论认为miR-138通过黏附介导的SGTA下调和细胞周期停滞促进CAM-DR表型。
要点
- NHL细胞与FN或HS-5黏附培养后miR-138表达显著高于悬浮培养组(P<0.05)。
- 过表达miR-138抑制野生型SGTA 3'UTR荧光素酶活性(0.73±0.03 vs 1.00±0.02,P=0.002),突变型无显著变化(P=0.241)。
- 35例DLBCL中进展/稳定患者miR-138表达显著高于完全/部分缓解患者(9.72±1.11 vs 3.06±0.22,P<0.001)。
核心结论
- 在黏附微环境中miR-138可通过靶向抑制SGTA诱导细胞周期G(1)期停滞促进CAM-DR进程。
研究设计与样本
- 以纤连蛋白(FN)或骨髓基质细胞HS-5构建NHL细胞黏附模型。
- 用Western blotting与RQ-PCR分析miR-138对SGTA蛋白及mRNA表达的影响。
- 双荧光素酶报告基因活性检测分析miR-138对SGTA mRNA 3′UTR活性的影响。
- 用Lv-shmiR-138、Lv-miR-138、Lv-Ctrl感染Daudi及OCI-Ly8细胞分析细胞周期、黏附能力及CAM-DR。
- 收集35例弥漫大B细胞淋巴瘤患者石蜡组织标本分析miR-138表达与疾病进展和耐药关系。
主要发现
- NHL细胞与FN或HS-5细胞黏附培养后miR-138表达水平显著高于悬浮培养组(P值均<0.05)。
- 下调miR-138表达可增强SGTA蛋白表达水平(P值均<0.05),对SGTA mRNA表达无显著影响(P值均>0.05)。
- 转染野生型SGTA 3′UTR载体时过表达miR-138显著抑制荧光素酶报告基因活性(0.73±0.03对1.00±0.02,t=0.914,P=0.002);转染突变型载体时无显著改变(0.93±0.04对1.00±0.02,t=1.375,P=0.241)。
- 悬浮及黏附培养状态下过表达miR-138可显著诱导Daudi及OCI-Ly8细胞G(1)期停滞(P值均<0.05)。
- 下调miR-138表达对Daudi及OCI-Ly8细胞黏附能力无显著影响(P值均>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the effects of miR-138 on the expression of small glutamine-rich TPR-containing protein A (SGTA) and cell adhesion-mediated drug resistance (CAM-DR) phenotype in non-Hodgkin's lymphoma (NHL). Methods: The adhesion model was constructed using fibronectin (FN) or bone marrow stromal cells HS-5. The effect of miR-138 on the expression of SGTA was analyzed by Western blotting and RQ-PCR. Dual-luciferase assays were performed to probe the effects of miR-138 on SGTA 3' UTR activities. Subsequently, we investigated the effect of miR-138 on cell cycle, adhesion ability and CAM-DR. Moreover, the correlation between miR-138 expression and therapeutic response was analyzed in 35 paraffin-embedded diffuse large B cell lymphoma samples. Results: Our data showed that adhesion of NHL cells to FN or HS-5 cells significantly increased miR-138 expression (P<0.05). Knockdown of miR-138 markedly increased the protein (all P<0.05) but not for mRNA (all P>0.05) levels of SGTA in NHL cell. The luciferase activity of SGTA 3' UTR was significantly suppressed by miR-138 transfected cells (0.73±0.03 vs 1.00±0.02, t=0.914, P=0.002). No change in terms of reporter activity was observed in SGTA 3'UTR mutant transfected cells (0.93±0.04 vs 1.00±0.02, t=1.375, P=0.241). Also we found that ectopic expression of miR-138 significantly induced cell cycle arrest at G(1) phase in both suspension and adherent cells (all P<0.05). Knockdown of miR-138 had no effect on cell adhesion ability (all P>0.05). More importantly, in suspension cells, knockdown of miR-138 significantly decreased the percentage of doxorubicin-induced cell death. However, knockdown of miR-138 dramatically increased the percentage of doxorubicin-induced cell death in FN/HS-5-adherent cells. Furthermore, the miR-138 expression was significantly higher in patients with progression of disease/stable disease than those experiencing complete response/partial response (9.72±1.11 vs 3.06±0.22, t=9.144, P<0.001). Conclusion: MiR-138 promoted CAM-DR phenotype through cell adhesion-mediated SGTA down-regulation and cell cycle arrest. 目的: 分析microRNA-138(miR-138)靶向调节小谷氨酰胺三角四肽重复区蛋白α(SGTA)对非霍奇金淋巴瘤(NHL)细胞黏附介导的耐药(cell adhesion-mediated drug resistance, CAM-DR)的影响。 方法: 以HS-5细胞或纤连蛋白(FN)构建NHL细胞黏附模型;Western blotting与RQ-PCR分析miR-138对SGTA蛋白及mRNA表达的影响;双荧光素酶报告基因活性检测分析miR-138对SGTA mRNA 3′UTR活性的影响;分别用miR-138下调慢病毒载体(Lv-shmiR-138)、miR-138过表达慢病毒载体(Lv-miR-138)、对照慢病毒载体(Lv-Ctrl)感染Daudi及OCI-Ly8细胞,分析miR-138对细胞周期、黏附能力及CAM-DR的影响;收集35例弥漫大B细胞淋巴瘤患者的石蜡组织标本,分析miR-138的表达情况及其与疾病进展和耐药关系。 结果: ①NHL细胞与FN或HS-5细胞黏附培养后miR-138表达水平显著高于悬浮培养组(P值均<0.05)。②下调miR-138的表达可增强SGTA蛋白的表达水平(P值均<0.05),而对SGTA mRNA的表达水平无显著影响(P值均>0.05)。③转染野生型SGTA 3′UTR载体时,过表达miR-138可显著抑制荧光素酶报告基因活性(0.73±0.03对1.00±0.02,t=0.914,P=0.002);而转染结合位点突变的突变型载体时,过表达miR-138不能显著改变报告基因活性(0.93±0.04对1.00±0.02,t=1.375,P=0.241)。④在悬浮及黏附培养状态下,过表达miR-138可显著诱导Daudi及OCI-Ly8细胞G(1)期停滞(P值均<0.05)。⑤下调miR-138的表达对Daudi及OCI-Ly8细胞的黏附能力均无显著影响(P值均>0.05)。⑥在悬浮培养状态下调miR-138的表达时,多柔比星诱导细胞死亡的比例显著下降,而在黏附培养状态下调miR-138的表达,多柔比星诱导细胞死亡的比例显著上升(P值均<0.05)。⑦miR-138在进展及稳定患者中的表达水平显著高于完全缓解以及部分缓解患者,差异具有统计学意义(9.72±1.11对3.06±0.22,t=9.144,P<0.001)。 结论: 在黏附微环境中miR-138可通过靶向抑制SGTA诱导细胞周期G(1)期停滞促进CAM-DR进程。.
引用
- Wu YX, He S, Xu XH, et al. [MicroRNA-138 regulates cell adhesion-mediated drug resistance phenotype by targeting SGTA in non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30180469. doi:10.3760/cma.j.issn.0253-2727.2018.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。